Does Rallies show Form 4 insider transactions for BCRX?

Yes. Rallies tracks BCRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BCRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BCRX. It does not provide personalized investment advice.

BCRX (BioCryst Pharmaceuticals Inc) Stock Analysis - Insider Trades

BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCRX trades at $8.80 with a market cap of $2.28B and a P/E ratio of -5.07. BCRX moved -0.34% today. Year to date, BCRX is +17.95%; over the trailing twelve months it is -15.39%. Its 52-week range spans $6.00 to $11.31. Analyst consensus is strong buy with an average price target of $22.43. Rallies surfaces BCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BCRX stock inside the company?

Recent BCRX insider activity includes Barnes Alane P sold 62.50K, HEGGIE THERESA sold 49.93K, Barnes Alane P sold 150.00K, Barnes Alane P sold 21.77K, and Barnes Alane P sold 21.21K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BCRX Key Metrics

Key financial metrics for BCRX
Metric	Value
Price	$8.80
Market Cap	$2.28B
P/E Ratio	-5.07
EPS	$-1.73
Dividend Yield	0.00%
52-Week High	$11.31
52-Week Low	$6.00
Volume	205
Avg Volume	0
Revenue (TTM)	$885.72M
Net Income	$-457.98M
Gross Margin	97.75%

Recent BCRX Insider Trades

Barnes Alane P sold 62.50K (~$596.25K) on May 13, 2026.
HEGGIE THERESA sold 49.93K (~$504.82K) on Mar 20, 2026.
Barnes Alane P sold 150.00K (~$1.37M) on Mar 16, 2026.
Barnes Alane P sold 21.77K (~$166.56K) on Dec 22, 2025.
Barnes Alane P sold 21.21K (~$162.26K) on Dec 15, 2025.

Latest BCRX News

BioCryst Reports $721.8M Q1 Loss, $156.4M Revenue and Strong ORLADEYO Sales — May 6, 2026
BioCryst Q1 ORLADEYO Revenue Up 11%; Europe Navenibart License Brings $70M — May 6, 2026
BioCryst Taps Sandeep Menon to Drive navenibart BLA, Astria Integration — Apr 6, 2026
BioCryst’s Price Target Raised to $22 as Q4 EPS Hits $1.12 on $406.5M Revenue — Mar 10, 2026
BioCryst Posts $601M ORLADEYO Revenue, $214M Profit and Pellets Launch — Mar 6, 2026

BCRX Analyst Consensus

8 analysts cover BCRX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $22.43.

Common questions about BCRX

Who is trading BCRX stock inside the company?: Recent BCRX insider activity includes Barnes Alane P sold 62.50K, HEGGIE THERESA sold 49.93K, Barnes Alane P sold 150.00K, Barnes Alane P sold 21.77K, and Barnes Alane P sold 21.21K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BCRX?: Yes. Rallies tracks BCRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BCRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BCRX. It does not provide personalized investment advice.